Research programme: amino acyl-tRNA synthetases - aTyr Pharma

Drug Profile

Research programme: amino acyl-tRNA synthetases - aTyr Pharma

Alternative Names: Amino acyl-tRNA synthetase splice variants - aTyr Pharma; AspRSlN1 (C76S); DRS1-154 (C76S); Homeokine; Physiocrines - aTyr Pharma; Resected amino acyl-tRNA synthetase - aTyr Pharma; Resected aspartyl-tRNA synthetase - aTyr Pharma; Tmax; Truncated aspartyl-tRNA synthetase - aTyr Pharma

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator aTyr Pharma
  • Class Amino acyl-tRNA synthetases; Aminoacyltransferases; Angiogenic proteins; Biological proteins; Proteins
  • Mechanism of Action Angiogenesis inducing agents; Cytokine receptor modulators; G protein-coupled receptor modulators; Histidine-tRNA ligase modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Immunological disorders; Inflammation; Metabolic disorders
  • Research Charcot-Marie-Tooth disease
  • No development reported Thrombocytopenia

Most Recent Events

  • 04 Nov 2015 Early research in Charcot-Marie-Tooth disease in USA (unspecified route)
  • 26 Mar 2014 Preclinical development is ongoing in USA
  • 21 Aug 2013 Preclinical development in Inflammation and Immunological disorders is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top